Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pemb... Read More
Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of P... Read More
Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Co... Read More
Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared ... Read More
Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemother... Read More
Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose S... Read More
Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating... Read More
Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Pl... Read More
Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solu... Read More
Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib ... Read More